Endurion Therapeutics, LLC
Advancing Oncology.  Improving Lives.

Endurion Therapeutics is a pharmaceutical company focused on novel products for the treatment of unmet medical needs and serious diseases.  

 

•ORIN1001 is the lead proprietary oral drug candidate for the treatment of cancer and IPF (idiopathic pulmonary fibrosis).

​

•ORIN1001 is poised to start Phase 2 clinical trials for the treatment of advanced solid tumors and metastatic breast cancer.  Phase 1 dose escalation trials have been completed in the US and China.

​​

•Our drug pipeline extends to other cancer types and serious diseases including, Idiopathic Pulmonary Fibrosis (IPF), inflammation and neurodegenerative disease.